Icu Medical earnings release, August 6, 2026

Icu Medical Inc (ICUI) · Form 8-K, Item 2.02 · Filed · SEC filing

ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance

SAN CLEMENTE, Calif., August 6, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2026.

Second Quarter 2026 Results

The following year-over-year results reflect the strategic divestiture of the IV Solutions business on May 1, 2025. Second quarter 2026 GAAP revenue increased 1% year-over-year; however, excluding the impact of the IV Solutions divestiture and foreign currency, non-GAAP organic revenue increased 6%.

Second quarter 2026 GAAP revenue was $551.7 million, as compared to $548.9 million in the same period in the prior year. GAAP gross profit for the second quarter of 2026 was $235.1 million, as compared to $208.1 million in the same period in the prior year. GAAP gross margin for the second quarter of 2026 was 43%, as compared to 38% in the same period in the prior year. GAAP net income for the second quarter of 2026 was $19.1 million, or $0.76 per diluted share, as compared to GAAP net income of $35.3 million, or $1.43 per diluted share, for the second quarter of 2025. Adjusted diluted earnings per share for the second quarter of 2026 was $2.37 as compared to $2.10 for the second quarter of 2025. Adjusted EBITDA was $110.0 million for the second quarter of 2026 as compared to $100.3 million for the second quarter of 2025.

Adjusted EBITDA and adjusted diluted earnings per share are measures calculated and presented on the basis of methodologies other than in accordance with GAAP. Please refer to the Use of Non-GAAP Financial Information following the financial statements herein for further discussion and reconciliations of these measures to GAAP measures.

Vivek Jain, ICU Medical’s Chief Executive Officer, said, “Second quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business."

Revenues by product line for the three and six months ended June 30, 2026 and 2025 were as follows (in millions):

*On May 1, 2025, we disposed of our IV Solutions business which was included within our Vital Care product line. Vital Care includes contract manufacturing revenue of $3.8 million and $8.2 million for the three and six months ended June 30, 2026, respectively, as compared to $5.3 million and $10.5 million for the three and six months ended June 30, 2025, respectively.

** Totals may differ from the income statement due to the rounding of product lines.

Fiscal Year 2026 Guidance

For Fiscal Year 2026 the Company is updating its estimates of GAAP net income from a range of $26 million to $44 million to a range of $73 million to $83 million and GAAP diluted earnings per share from a range of $1.03 to $1.74 to a range of $2.89 to $3.29. The Company is updating the estimate of its full year 2026 guidance of Adjusted EBITDA from a range of $400 million to $430 million to a range of $415 million to $435 million and diluted earnings per share from a range of $7.75 to $8.45 to a range of $8.60 to $9.00.

Conference Call

The Company will host a conference call to discuss its second quarter financial results, today at 4:30 p.m. ET (1:30 p.m. PT). The call can be accessed at (800) 420-1459, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's website at www.icumed.com, clicking on the Investors tab, clicking on Event Calendar and clicking on the Webcast icon and following the prompts. The webcast will also be available by replay.

About ICU Medical

ICU Medical (Nasdaq: ICUI) is a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical can be found at www.icumed.com.

Financial statements

Income Statement

Three months ended June 30, — (In thousands, except per share data)

Three months ended June 30, – 2026Three months ended June 30, – 2025Six months ended June 30, – 2026Six months ended June 30, – 2025
TOTAL REVENUES551,683548,8661,081,9081,153,568
COST OF GOODS SOLD316,630340,802640,629735,395
GROSS PROFIT235,053208,064441,279418,173
OPERATING EXPENSES:Selling, general and administrative151,922159,392306,488316,625
OPERATING EXPENSES:Research and development22,70221,86743,98245,158
OPERATING EXPENSES:Restructuring, strategic transaction and integration21,30216,21838,10332,915
OPERATING EXPENSES:TOTAL OPERATING EXPENSES195,926197,477388,573394,698
OPERATING EXPENSES:INCOME FROM OPERATIONS39,12710,58752,70623,475
OPERATING EXPENSES:INTEREST EXPENSE, net-15,747-20,549-32,241-42,580
OPERATING EXPENSES:OTHER (EXPENSE) INCOME, net-2361,818-1,29655
OPERATING EXPENSES:GAIN ON SALE OF BUSINESS41,82341,823
OPERATING EXPENSES:INCOME BEFORE INCOME TAXES AND EQUITY IN EARNINGS OF UNCONSOLIDATED AFFILIATES23,14433,67919,16922,773
OPERATING EXPENSES:(PROVISION) BENEFIT FOR INCOME TAXES-7,070-1,17827,644-5,748
OPERATING EXPENSES:NET INCOME FROM CONSOLIDATED COMPANIES16,07432,50146,81317,025
OPERATING EXPENSES:EQUITY IN EARNINGS OF UNCONSOLIDATED AFFILIATES3,0132,8372,4062,837
OPERATING EXPENSES:NET INCOME19,08735,33849,21919,862
NET INCOME PER SHAREBasic0.761.431.980.81
NET INCOME PER SHAREDiluted0.761.431.960.8
WEIGHTED AVERAGE NUMBER OF SHARESBasic25,00024,64524,88424,593
WEIGHTED AVERAGE NUMBER OF SHARESDiluted25,04424,70825,13224,746

Income Statement

(In thousands) (in thousands)

Adjusted EBITDA – Three months ended June 30, – 2026Adjusted EBITDA – Three months ended June 30, – 2025
GAAP net income19,08735,338
Non-GAAP adjustments:Interest, net15,74720,549
Non-GAAP adjustments:Stock compensation expense11,87014,457
Non-GAAP adjustments:Depreciation and amortization expense49,61449,665
Non-GAAP adjustments:Restructuring, strategic transaction and integration21,30216,218
Non-GAAP adjustments:Settlements30150
Non-GAAP adjustments:Quality system and product-related remediation5,8905,706
Non-GAAP adjustments:Gain on sale of business-41,823
Non-GAAP adjustments:Noncash release of loss on contract provision-1,120-717
Non-GAAP adjustments:Gross profit on contract manufacturing-575-412
Non-GAAP adjustments:Tariff refunds-18,888
Non-GAAP adjustments:Provision for income taxes7,0701,178
Non-GAAP adjustments:Total non-GAAP adjustments90,94064,971
Non-GAAP adjustments:Adjusted EBITDA110,027100,309

Income Statement

The Company’s U.S. GAAP results for the three months ended June 30, 2026 included special items which impacted the U.S. GAAP measures as follows:

Total revenuesGross profitSelling, general and administrativeResearch and developmentRestructuring, strategic transaction and integrationIncome from operationsInterest expense, netIncome before income taxes and equity in income of unconsolidated affiliatesProvision for income taxesProvision for income taxesNet income from consolidated companiesEquity in earnings of unconsolidated affiliatedNet income (loss)Diluted earnings (loss) income per share
Reported (GAAP)551,683235,053151,92222,70221,30239,127-15,74723,144-7,07016,0743,01319,0870.76
Reported percent of total revenues or (percent of income (loss) before income taxes and equity in earnings of unconsolidated affiliates)4328447-3430.530.5%3
Contract manufacturing-3,799-575-575-575141-434-434-0.02
Stock compensation expense1,850-9,249-77111,87011,870-2,8798,9918,9910.36
Amortization expense1,265-31,72232,98732,987-8,20024,78724,7870.99
Restructuring, strategic transaction and integration-21,30221,30221,302-5,04916,25316,2530.65
Settlements-303030-72323
Quality system and product-related remediation5,8905,8905,890-1,2654,6254,6250.18
Noncash release of loss on contract provision1,120-1,120318-802196-606-606-0.02
Tariff refunds-18,888-18,888-710-19,5984,802-14,796-14,796-0.59
Tax benefit from discrete reserve release and valuation allowance*1,5481,5481,5480.06
Tax benefit from equity in loss of unconsolidated affiliates738738-738
Adjusted (Non-GAAP)**547,884224,595112,04121,931$—90,623-16,13974,248-17,04557,2032,27559,4782.37
Adjusted percent of total revenues or (percent of (loss) income before income taxes and equity in loss of unconsolidated affiliates for benefit (provision) for income taxes)4120417-3142323.0%10

Income Statement

(In thousands) (in thousands)

Net Debt – As of June 30, 2026TTM Adjusted EBITDA – As of June 30, 2026Net Leverage RatioNet Debt – As of June 30, 2026TTM Adjusted EBITDA – As of June 30, 2026Net Leverage Ratio
Net Leverage Ratio CalculationCurrent portion of long-term debt18,750
Net Leverage Ratio CalculationLong-Term Debt1,212,449
Net Leverage Ratio CalculationTotal GAAP Long-Term Debt1,231,199
Net Leverage Ratio CalculationAdd: Unamortized Debt Issuance Costs/Discounts(1)8,614
Net Leverage Ratio CalculationLess: Cash and cash equivalents-298,299
Net Leverage Ratio CalculationNet Debt (Non-GAAP)941,514
(1) Represents unamortized debt issuance costs and original issue discounts deducted from the carrying value of long-term debt on the Condensed Consolidated Balance Sheets in accordance with U.S. GAAP. Management adds back these costs to present total contractual principal obligations outstanding when evaluating debt leverage.GAAP net income30,089
Non-GAAP adjustments:Interest, net72,692
Non-GAAP adjustments:Stock compensation expense55,003
Non-GAAP adjustments:Depreciation and amortization expense201,273
Non-GAAP adjustments:Restructuring, strategic transaction and integration71,693
Non-GAAP adjustments:Settlements1,596
Non-GAAP adjustments:Quality system and product-related remediation38,070
Non-GAAP adjustments:Asset write-offs and similar charges887
Non-GAAP adjustments:Gain on sale of business-2,969
Non-GAAP adjustments:Noncash release of loss on contract provision-4,392
Non-GAAP adjustments:Gross profit on contract manufacturing-1,292
Non-GAAP adjustments:Tariff refunds-18,888
Non-GAAP adjustments:Provision for income taxes-30,955
Non-GAAP adjustments:Total non-GAAP adjustments382,718
Non-GAAP adjustments:TTM Adjusted EBITDA412,807
Non-GAAP adjustments:Net Debt941,514
Non-GAAP adjustments:Divided by: TTM Adjusted EBITDA412,807
Non-GAAP adjustments:Net Leverage Ratio2.28

Income Statement

(In millions, except per share data)

Low End of GuidanceHigh End of Guidance
GAAP net income7383
Non-GAAP adjustments:Interest, net6565
Non-GAAP adjustments:Stock compensation expense5050
Non-GAAP adjustments:Depreciation and amortization expense203203
Non-GAAP adjustments:Restructuring, strategic transaction and integration5252
Non-GAAP adjustments:Quality and regulatory initiatives and remediation2525
Non-GAAP adjustments:Noncash release of loss on contract provision-4-4
Non-GAAP adjustments:Gross profit on contract manufacturing-2-2
Non-GAAP adjustments:Tariff refunds-19-19
Non-GAAP adjustments:Benefit for income taxes-28-18
Non-GAAP adjustments:Total non-GAAP adjustments342352
Non-GAAP adjustments:Adjusted EBITDA415435
Non-GAAP adjustments:GAAP income per share2.893.29
Non-GAAP adjustments:Stock compensation expense1.981.98
Non-GAAP adjustments:Amortization expense5.285.28
Non-GAAP adjustments:Restructuring, strategic transaction and integration2.062.06
Non-GAAP adjustments:Quality and regulatory initiatives and remediation0.990.99
Non-GAAP adjustments:Noncash release of loss on contract provision-0.12-0.12
Non-GAAP adjustments:Gross profit on contract manufacturing-0.08-0.08

Balance Sheet

(In thousands) (in thousands)

June 30, 2026December 31, 2025
CURRENT ASSETS:Cash and cash equivalents298,299307,963
CURRENT ASSETS:Accounts receivable, net of allowance for doubtful accounts183,531180,515
CURRENT ASSETS:Inventories607,421615,859
CURRENT ASSETS:Prepaid expenses and other current assets121,65786,217
CURRENT ASSETS:TOTAL CURRENT ASSETS1,210,9081,190,554
CURRENT ASSETS:PROPERTY, PLANT AND EQUIPMENT, net446,798451,817
CURRENT ASSETS:OPERATING LEASE RIGHT-OF-USE ASSETS38,61054,470
CURRENT ASSETS:GOODWILL1,484,3841,499,754
CURRENT ASSETS:INTANGIBLE ASSETS, net567,665633,559
CURRENT ASSETS:DEFERRED INCOME TAXES25,56925,891
CURRENT ASSETS:OTHER ASSETS63,43562,877
CURRENT ASSETS:INVESTMENTS IN UNCONSOLIDATED AFFILIATES133,913131,586
CURRENT ASSETS:TOTAL ASSETS3,971,2824,050,508
CURRENT LIABILITIES:Accounts payable149,165154,374
CURRENT LIABILITIES:Accrued liabilities322,489315,337
CURRENT LIABILITIES:Current portion of long-term debt18,75018,750
CURRENT LIABILITIES:Income tax payable7,96010,400
CURRENT LIABILITIES:TOTAL CURRENT LIABILITIES498,364498,861
CURRENT LIABILITIES:LONG-TERM DEBT1,212,4491,265,917
CURRENT LIABILITIES:OTHER LONG-TERM LIABILITIES70,99489,536
CURRENT LIABILITIES:DEFERRED INCOME TAXES12,22737,756
CURRENT LIABILITIES:INCOME TAX LIABILITY25,39734,613
STOCKHOLDERS’ EQUITY:Common stock, $0.10 par value; Authorized — 80,000 shares; Issued —25,186 and 24,688 shares at June 30, 2026 and December 31, 2025, respectively, and outstanding — 25,007 and 24,688 shares at June 30, 2026 and December 31, 2025, respectively2,5192,469
STOCKHOLDERS’ EQUITY:Additional paid-in capital1,475,9741,465,118
STOCKHOLDERS’ EQUITY:Treasury stock, at cost-23,415-22
STOCKHOLDERS’ EQUITY:Retained earnings740,109690,890
STOCKHOLDERS’ EQUITY:Accumulated other comprehensive loss-43,336-34,630
STOCKHOLDERS’ EQUITY:TOTAL STOCKHOLDERS' EQUITY2,151,8512,123,825
STOCKHOLDERS’ EQUITY:TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY3,971,2824,050,508

Cash Flow

Six months ended June 30, — (In thousands) (in thousands)

Six months ended June 30, – 2026Six months ended June 30, – 2025
CASH FLOWS FROM OPERATING ACTIVITIES:Net income49,21919,862
Adjustments to reconcile net loss to net cash provided by operating activities:Depreciation and amortization99,64099,110
Adjustments to reconcile net loss to net cash provided by operating activities:Noncash lease expense8,1369,308
Adjustments to reconcile net loss to net cash provided by operating activities:Stock compensation25,88126,636
Adjustments to reconcile net loss to net cash provided by operating activities:Loss on disposal of property, plant and equipment and other assets1,9831,753
Adjustments to reconcile net loss to net cash provided by operating activities:Debt issuance costs amortization1,5743,482
Adjustments to reconcile net loss to net cash provided by operating activities:Undistributed equity in earnings of unconsolidated affiliates-2,406-2,837
Adjustments to reconcile net loss to net cash provided by operating activities:Gain on sale of business-41,823
Adjustments to reconcile net loss to net cash provided by operating activities:Other13,4718,037
Changes in operating assets and liabilities, net of amounts acquired:Accounts receivable-7,56216,691
Changes in operating assets and liabilities, net of amounts acquired:Inventories4,625-29,213
Changes in operating assets and liabilities, net of amounts acquired:Prepaid expenses and other current assets-16,461-9,208
Changes in operating assets and liabilities, net of amounts acquired:Other assets-2,936-5,682
Changes in operating assets and liabilities, net of amounts acquired:Accounts payable-4,90914,382
Changes in operating assets and liabilities, net of amounts acquired:Accrued liabilities-5,895-19,835
Changes in operating assets and liabilities, net of amounts acquired:Income taxes, including excess tax benefits and deferred income taxes-45,301-28,125
Changes in operating assets and liabilities, net of amounts acquired:Net cash provided by operating activities119,05962,538
CASH FLOWS FROM INVESTING ACTIVITIES:Purchases of property, plant and equipment-29,813-34,317
CASH FLOWS FROM INVESTING ACTIVITIES:Proceeds from the sale of business209,464
CASH FLOWS FROM INVESTING ACTIVITIES:Deposit received for the sale of a business2,000
CASH FLOWS FROM INVESTING ACTIVITIES:Proceeds from sale of assets2242
CASH FLOWS FROM INVESTING ACTIVITIES:Intangible asset additions-3,555-4,541
CASH FLOWS FROM INVESTING ACTIVITIES:Net cash (used in) provided by investing activities-31,346170,648
CASH FLOWS FROM FINANCING ACTIVITIES:Principal repayments of long-term debt-54,688-247,750
CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from exercise of stock options4905,972
CASH FLOWS FROM FINANCING ACTIVITIES:Payments on finance leases-1,297-885
CASH FLOWS FROM FINANCING ACTIVITIES:Tax withholding payments related to net share settlement of equity awards-38,862-8,688
CASH FLOWS FROM FINANCING ACTIVITIES:Net cash used in financing activities-94,357-251,351
CASH FLOWS FROM FINANCING ACTIVITIES:Effect of exchange rate changes on cash-3,0209,624

Cash Flow

(In thousands) (in thousands)

Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow – Three months ended June 30, – 2026Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow – Three months ended June 30, – 2025Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow – Six months ended June 30, – 2026Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow – Six months ended June 30, – 2025
Net cash provided by operating activities80,15011,211119,05962,538
Purchase of property, plant and equipment-18,511-19,696-29,813-34,317
Proceeds from sale of assets212242
Free cash flow61,660-8,48589,26828,263
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as

“aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” or the negative thereof or comparable terminology and may include (without limitation) information regarding the Company's expectations, goals and intentions regarding the future and financial outlook for 2026. These forward-looking statements are based on management's current expectations, estimates, forecasts and projections about the Company and assumptions management believes are reasonable, all of which are subject to risks and uncertainties that could cause actual results and events to differ materially from those stated in the forward-looking statements. These risks and uncertainties include, but are not limited to: risks from doing business in foreign countries, including related to tariffs and other barriers to trade; the Company’s ability to compete successfully, including with larger international companies and established local companies; decreased demand for the Company's products; costs related to product development; cost volatility or potential loss of supply of raw materials due to our dependence on single and limited source third-party suppliers; ability to achieve operating efficiencies; risks related to significant sales through our distributors; inflation and foreign currency exchange rates; impacts from global macroeconomic and geopolitical conditions, including from escalated conflicts in the Middle East and associated disruptions to shipping and increased oil costs; healthcare costs and reimbursement levels; disruptions at the FDA and other governmental agencies; damage at the Company’s manufacturing or supply facilities; risks associated with the IV Solutions joint venture and the Smiths Medical integration; risks associated with the timing and resolution of the 2025 warning letter; risks related to protection of our information technology systems and compliance with privacy laws and regulations; risks related to our intellectual property; and the other important factors described under “Risk Factors” in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and our subsequent filings with the SEC. Forward-looking statements contained in this press release are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise unless required by law.

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.